MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--GPC Biotech AG (Frankfurt Stock Exchange: GPC) today reported that pre-clinical data on RGB-286638, the Company’s multi-targeted protein kinase inhibitor, are being presented at the American Association for Cancer Research (AACR) 100th Annual Meeting in Denver, Colorado. Researchers from the Dana-Farber Cancer Institute and the Massachusetts General Hospital Cancer Center (MGH), Boston, Massachusetts gave an oral presentation entitled, “A Novel Multi-Targeted Small Molecule Inhibitor RGB-286638 Triggers Apoptosis and Necrosis in Multiple Myeloma via Dual Cell Death Pathways.” The data show that RGB-286638 demonstrates in vivo activity in several pre-clinical models of multiple myeloma. The compound also induces cell death in multiple myeloma cells independent from the p53 status; p53 is a gene involved in the control of cell proliferation.
